Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials ...

a Durable platelet response was defined as a platelet count of > 50 x 10 9 platelets/L for 6 of the last 8 weeks of the 24-week study period, with no rescue medication administered during the ...

Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The ...

Data from the completed Phase 1/2 GALILEO-1 clinical trial of FLT201 have shown improvements across a number of key biomarkers and clinical assessments. Positive interim results for a clinical trial ...